Obesity

liver

Biotech

South Korean biotech's GLP-1 scores MASH win, reduces weight

D&D Pharmatech tested a once-weekly regimen of its dual GLP-1/glucagon receptor agonist DD01 in 67 overweight or obese patients with MASH.

James Waldron Jun 16, 2025 7:22am

Ozempic syringe pen and measuring tape on blue background

Novo plots ph. 3 trials for next-gen obesity asset amycretin

Jun 13, 2025 10:35am

Anatomical model of human arm and torso showing muscle

Eli Lilly inks $650M Juvena pact to find muscle-boosting drugs

Jun 11, 2025 7:30am

Graphic images of white and black puzzle pieces connecting seamlessly

Eli Lilly taps Camurus' tech to advance long-acting obesity meds

Jun 3, 2025 5:04pm

finance numbers tape money

Regeneron pens $2B pact for Hansoh's potential rival to Zepbound

Jun 2, 2025 8:20am

Illustration of the concept of layoff and downsizing of staff

Biomea cuts staff, drops leukemia asset in metabolic shift

May 5, 2025 6:59pm